Eliem Therapeutics: Funding, Investors & Team (Sep 2026)
Eliem Therapeutics is a biotechnology company that is in the clinical stage of development and focuses on creating treatments for disorders of the nervous system. The company utilizes its knowledge in neuroscience, translational medicine, and clinical development to address the medical need in this area with an innovative pipeline. Eliem Therapeutics works on developing and bringing to market drug candidates that could potentially be the best in their class for treating disorders related to neuronal excitability. These disorders, including chronic pain, depression, epilepsy, and anxiety, significantly impact the lives of millions of individuals daily. The primary motivation of the Eliem team is to provide patients with the opportunity to lead happier and more fulfilling lives.
Eliem Therapeutics has raised $180M across 2 funding rounds on record, the most recent an undisclosed round of $120M announced in Apr 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Eliem Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2024.
Eliem Therapeutics Funding Rounds
Eliem Therapeutics raised $60.0M in an undisclosed round announced in May 2021.
2.9 years later, an undisclosed round of $120M was announced in Apr 2024.
Eliem Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Eliem Therapeutics Funding Compared to Other Biotechnology Startups
Eliem Therapeutics' latest round of $120M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Eliem Therapeutics in Biotechnology and Redmond
Companies Similar to Eliem Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Eliem Therapeutics Funding FAQs
What does Eliem Therapeutics do?
Eliem Therapeutics is a biotechnology company that is in the clinical stage of development and focuses on creating treatments for disorders of the nervous system. The company utilizes its knowledge in neuroscience, translational medicine, and clinical development to address the medical need in this area with an innovative pipeline. Eliem Therapeutics works on developing and bringing to market drug candidates that could potentially be the best in their class for treating disorders related to neuronal excitability. These disorders, including chronic pain, depression, epilepsy, and anxiety, significantly impact the lives of millions of individuals daily. The primary motivation of the Eliem team is to provide patients with the opportunity to lead happier and more fulfilling lives.
How much funding has Eliem Therapeutics raised?
Eliem Therapeutics has raised $180M across 2 rounds on record. The most recent is an undisclosed round of $120M announced in Apr 2024.
When did Eliem Therapeutics last raise funding?
Eliem Therapeutics' most recent funding round on record is an undisclosed round of $120M, announced in Apr 2024.
Who founded Eliem Therapeutics?
FundedIQ lists Valerie Morisset (Founder) at Eliem Therapeutics.
Who is the CEO of Eliem Therapeutics?
Bob Azelby is listed as CEO at Eliem Therapeutics.
Where is Eliem Therapeutics headquartered?
Eliem Therapeutics is based in Redmond, Washington, United States.
How many employees does Eliem Therapeutics have?
Eliem Therapeutics is in the 11-50 employee band.
How does Eliem Therapeutics' funding compare to other Biotechnology startups?
Eliem Therapeutics' latest round of $120M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Eliem Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Eliem Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.